AA
HRMY icon

ALPS Advisors’s Harmony Biosciences HRMY Stock Holding History

ALPS Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,199
Closed -$531K – 1086
2025
Q4 		$531K Buy
14,199
+122
+0.9% +$4.01K ﹤0.01% 708
2025
Q3 		$388K Buy
14,077
+3,476
+33% +$120K ﹤0.01% 924
2025
Q2 		$335K Buy
10,601
+128
+1% +$4.12K ﹤0.01% 896
2025
Q1 		$348K Buy
10,473
+1,229
+13% +$44.1K ﹤0.01% 805
2024
Q4 		$318K Hold
9,244
– – ﹤0.01% 855
2024
Q3 		$370K Sell
9,244
-1,984
-18% -$69.7K ﹤0.01% 744
2024
Q2 		$339K Sell
11,228
-59
-0.5% -$1.77K ﹤0.01% 767
2024
Q1 		$379K Buy
11,287
+2,895
+34% +$92.9K ﹤0.01% 665
2023
Q4 		$271K Sell
8,392
-478
-5% -$13.3K ﹤0.01% 906
2023
Q3 		$291K Buy
+8,870
New +$308K ﹤0.01% 893
2023
Q1 		– Sell
-6,880
Closed -$379K – 1074
2022
Q4 		$379K Sell
6,880
-27
-0.4% -$1.49K ﹤0.01% 698
2022
Q3 		$306K Buy
+6,907
New +$337K ﹤0.01% 751

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

ALPS Advisors's HRMY Position: Q1 2026 in Review

ALPS Advisors sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 14,199 shares — an estimated $531K sold.

ALPS Advisors first reported a position in HRMY in Q3 2022 and held it in 12 quarters. The position peaked at $531K in Q4 2025. 311 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • ALPS Advisors reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • ALPS Advisors sold 14,199 Harmony Biosciences shares in Q1 2026, an estimated $531K.
  • ALPS Advisors first reported a position in Harmony Biosciences in Q3 2022 and held it in 12 quarters.
  • ALPS Advisors's Harmony Biosciences position peaked at $531K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.